Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- Forzinity 40 mg once daily by subcutaneous injection for Barth syndrome patients weighing ≥30 kg.
Dose evidence detail — Elamipretide
Detailed dose evidence documented for Elamipretide in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
- BTHS: 40 mg SC daily (studied in TAZPOWER).
- Preclinical HF: IV dosing in animal models.
Not established
What is not established
- Uses beyond Barth syndrome are not approved, and no regimen is established for those conditions. Current product use is limited to the exact labeled indication, population, formulation, and route; other study exposures are not recommendations.
Elamipretide — sección de dosis y administración de la monografía